FDA, USPTO Collaboration Could Expand Review Of Pharma Patents, Explore ‘Skinny Label’ Policy

 
• By Brenda Sandburg
Patent collaboration
US FDA and USPTO team up to assure patents do not delay generic and biosimilar competition • Source: Shutterstock

More from Legal & IP

More from Pink Sheet